

Press release

2022-09-01



## Genetic Analysis appoints Sedermera Corporate Finance AB to act as a liquidity provider for the Company's share

Oslo, Norway, September 1, 2022 – Genetic Analysis AS (“GA” or “the Company”) has appointed Sedermera Corporate Finance as the Company’s liquidity provider. The assignment will commence on the 5 September 2022 and Sedermera will continuously place trading items on both bid and ask side in the order book for the Genetic Analysis share and ensure that a predetermined spread is maintained in the share. The purpose of the liquidity providing is to promote good liquidity and ensure a low spread between the bid and ask price in current trading.

**For further information, please contact:**

Ronny Hermansen, CEO

E-mail: [rh@genetic-analysis.com](mailto:rh@genetic-analysis.com)

Eilert Aamodt, Chief Financial Officer

E-mail: [ea@genetic-analysis.com](mailto:ea@genetic-analysis.com)

**About Genetic Analysis**

Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 10 years of expertise in research and product development. The unique GA-map® platform is based on a pre-determined multiplex targets approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need for further bioinformatics work. GA’s vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA employs a team of highly qualified employees with scientific backgrounds and competence in bioinformatics, molecular biology, and bioengineering.

For more information, visit Genetic Analysis’ webpage: [www.genetic-analysis.com](http://www.genetic-analysis.com)